ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO690

Incidence of Primary Immunoglobulin A Nephropathy (IgAN) Among a Diverse Population in the United States

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Sim, John J., Kaiser Permanente Southern California, Pasadena, California, United States
  • Chen, Qiaoling, Kaiser Permanente Southern California, Pasadena, California, United States
  • Chang, John M., Kaiser Permanente Southern California, Pasadena, California, United States
  • Cannizzaro, Nancy, Kaiser Permanente Southern California, Pasadena, California, United States
  • Makhija, Dilip, Otsuka America Pharmaceutical Inc, Rockville, Maryland, United States
  • Fernandes, Ancilla, Otsuka America Pharmaceutical Inc, Rockville, Maryland, United States
  • Bhattacharjee, Sandipan, Otsuka America Pharmaceutical Inc, Rockville, Maryland, United States
  • Pinto, Cibele S., Otsuka America Pharmaceutical Inc, Rockville, Maryland, United States
  • Schachter, Asher Daniel, Visterra Inc, Waltham, Massachusetts, United States
  • Mathur, Mohit, Visterra Inc, Waltham, Massachusetts, United States
Background

IgAN is a leading cause of primary glomerular disease and end stage kidney disease (ESKD) with a 10-year risk of chronic kidney disease (CKD) progression of up to 40%. Global incidence is estimated at 2-5 cases per 100,000 people. US data suggest lower rates but varies by race/ethnicity. We examined incidence of primary IgAN, leveraging a diverse, contemporary cohort from a single integrated health system in California.

Methods

A retrospective cohort was studied (1/1/2010-12/31/2021) of Kaiser Permanente members with biopsy proven IgAN, excluding secondary IgAN. Annual IgAN incidence rates were standardized by age, sex, and race/ethnicity according to the 2020 US Census using the American Community Survey (ACS). Primary IgAN rate was calculated for 2010-2021 and stratified by race/ethnicity. We estimated IgAN prevalence by using mean annual incidence x estimated disease duration.

Results

A total of 606 primary IgAN patients were identified with mean age (SD) of 46 years (15.0) with males (51.2%), Hispanic/Latinos (38.6%), Asian/Pacific Islanders (30.4%), Whites (25.6%), and Blacks (3.1%). The average annual incidence rate (per 100,000 person-years) of primary IgAN was 4.5, 1.7, 1.2, and 0.6 among Asian/Pacific Islanders, Hispanic/Latino, Whites, and Blacks, respectively. The mean annual IgAN incidence of 1.4 per 100,000 person-years equates to an adjusted IgAN prevalence estimate of 40 per 100,000 persons (incidence x estimated disease duration of 28.5 years for IgAN patients).

Conclusion

Our findings show a mean annual IgAN incidence of 1.4 per 100,000 person-years. Asian/Pacific Islander and Hispanic/Latino had the highest incidence rate of IgAN. Whether the clinical course and response to treatment for IgAN patients varies by race/ethnicity warrants further investigation.

Funding

  • Commercial Support – Otsuka Pharmaceuticals